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Opinion statement
There are only two currently approved classes of hepatitis B virus (HBV) antiviral agents,
pegylated interferon (Peg-IFN), and nucleos(t)ide analogs (NAs) for chronic HBV infec-
tion. Although Peg-IFN is used for a finite 48-week duration and offers a greater chance of
sustained off-treatment virological response, it is poorly tolerated and can only be offered
to selected patients. The NAs are well tolerated but require prolonged therapy due to risk
of relapse with treatment cessation. There is evolving data that novel virological assays
(e.g., quantitative hepatitis B surface antigen, quantitative hepatitis B core antigen,
quantitative antibody to core protein) in combination with hepatitis B genotype and more
sensitive HBV DNA polymerase chain reaction (PCR) assays may be useful to predict
response to IFN as well as off-treatment NA durability. Utilization of these clinical
laboratory tests may be important given the development of novel anti-HBV therapies,
hoping to achieve a cure for chronic hepatitis B infection.
Introduction
Hepatitis B virus (HBV) infection is estimated to affect
approximately 0.8–1.1 % of Canadians [1, 2]. Antiviral
treatments approved and available in Canada for chronic
hepatitis B (CHB) infection include interferon (standard
or pegylated interferon (Peg-IFN)) and nucleos(t)ide an-
alogs (NAs), including an L-nucleoside analog
(lamivudine (LAM)), acyclic nucleoside phosphonates
(adefovir dipivoxil (ADV) and tenofovir disoproxil fuma-
rate (TDF)), and a D-cyclopentane class nucleoside analog
(entecavir (ETV)) [3]. Although most Canadian provinces
and territories provide somemeasure of health plan reim-
bursement or coverage for these treatments, there may be
strict clinical restrictions imposed for reimbursement, es-
pecially for more expensive second-generation NA (i.e.,
TDF and ETV), which limits their use and effectiveness [4–
6]. Treatment is normally restricted to CHB carriers in a
prolonged immune-active phase of infection or with ad-
vanced liver disease. In both HBV e antigen (HBeAg)-
positive and HBeAg-negative patients, clinicians assess
on-treatment response to NA by monitoring serum HBV
DNA (i.e., suppression of viral replication), antibody to
HBeAg (anti-HBe) seroconversion (in HBeAg-positive pa-
tients), normalization of serum liver transaminases, and
improvement in liver stiffness or histology, as determined
by transient elastography (FibroScan®) or liver biopsy [7•,
8]. Large randomized clinical trials have demonstrated
that achievement of these surrogate clinical endpoints
lead to reduced risk of liver disease progression, hepato-
cellular carcinoma (HCC) development, and even fibrosis
regression [9, 10]. In contrast, the assessment of response
to Peg-IFN therapy is mainly based on off-treatment viro-
logical and clinical markers. Thus, a Bsustained virologic
response^ (SVR) to Peg-IFN therapy is defined as HBeAg
loss (in HBeAg-positive patients), HBV DNA G2000 IU/
mL, as well as persistent normalization of alanine amino-
transferase (ALT) at 6 months after the end of treatment.
HBsAg loss is rare but more likely to occur with Peg-IFN
compared to NA treatment [11]. As discussed below,
recent data indicate that quantitative hepatitis B surface
antigen (qHBsAg), as well as HBV DNA testing, could
predict SVR to Peg-IFN therapy and NA. Table 1 describes
the summary of current international guidelines for NA
cessation and definitions of treatment response and re-
lapse following withdrawal.
This review will provide a comprehensive over-
view of clinical virological tests used in monitoring
Table 1. Summary of current international guidelines for NA treatment cessation
Guideline HBeAg (+) HBeAg (−)
CASL/American Association for the
Study of Liver Diseases (AASLD)
Non-cirrhotic
- Anti-HBe seroconversion
- Stop NA after consolidation
(Normal ALT and DNA neg × 1–3 years)
- Monitor q 3-month × 1 year
- OR Rx until HBsAg loss
Cirrhotic
- Continue Rx
- May consider if HBsAg loss
- Monitor ALT monthly
Non-Cirrhotic
- Continue until HBsAg loss
- Monitor ALT q 3 months × 1 year
Cirrhotic
- Consider if HBsAg loss
- Risk flares unknown
- Monitor ALT monthly
EASL - Similar to AASLD
- Only if Rx with potent second-generation
NA (TDF, ETV)
- Durable off-treatment response in 40-80 %
- Similar to AASLD
- Continue until HBsAg loss
- Indefinitely in cirrhotic
APASL - Stop 1 year—ideally 3 years after HBeAg
seroconversion
- continue until HBV DNA neg × 3,
6 months apart
Definitions: viral relapse: HBV DNA 92000 IU/mL after stopping Rx in patients with virological response. Clinical relapse: viral relapse along with
ALT 92 × ULN or baseline ALT. Sustained response: HBV DNA G200 IU/mL and ALT normal after stopping therapy. Complete response: sustained
off-treatment virological response, together with loss of HBsAg
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response to antiviral therapy for CHB infection,
including the current assays for HBV DNA, more
recent novel assays such as qHBsAg, and potential
monitoring assays (Table 2).
HBV DNA monitoring
Monitoring of virological, serological, and clinical markers of infection during
treatment and following its withdrawal is essential in evaluating treatment
efficacy and patient response. Monitoring of serum HBV DNA has long been
considered the best viral marker for management of chronic infection, due to
the fundamental role of HBV DNA levels in disease progression and the
persistent suppression of HBV DNA as a reliable endpoint goal of antiviral
therapy [12•]. Long-term population-based studies have demonstrated the
importance of serum HBV DNA levels in predicting the risk for development
of severe end-stage liver disease outcomes [13]. Sensitive monitoring of HBV
DNAduring treatment has also established that stable suppression ofHBVDNA
to low or undetectable levels improves histologic outcomes and reverses fibrosis
or cirrhosis [8, 14]. Treatment management has been facilitated by improve-
ment in HBV DNA quantitative technologies, allowing for increased sensitivity
and dynamic range. Most clinical laboratories utilize commercially available
real-time polymerase chain reaction (PCR) methods having sensitive limits of
detection and quantification for measuring serum HBV DNA; however, other
technologies, such as digital PCR, are being investigated as alternative methods,
although standardization, ease of use, and optimization will be required to
match the convenience and sensitivity of real-time PCR [15, 16].
HBV DNA LoD and undetectable HBV DNA
Assay sensitivity, which determines the limit of HBV DNA detection and quan-
tification, differs among commercial assays; thus, the definition of
Bundetectable DNA^ in the literature and management guidelines will vary.
Prior to the development of an HBV DNA standard IU for quantification,
genome equivalents or copies were used, often resulting in significant variability
among assays [17, 18]. Due to this variability and use of assays having lower
limits of detection, the findings of earlier studies investigating treatment re-
sponse and cessationmay not be comparable to later studies involving sensitive
real-time PCR assays [19, 20].
Most management guidelines define virological response as Bundetectable
HBV DNA as measured by a sensitive PCR assay^ [21, 22]. Practically, this
translates into a range of values based on the detection limits of quantitative
real time HBV PCR assays [23•]. Prior to 2007, most commercially available
quantitative HBV DNA assays had a relatively narrow linear range and limit of
detection (LoD) of approximately 200 IU/mL. Current real-time PCR assays
have an 8 log10 linear range with very low LoD: G6 IU/mL (Roche Cobas High
Pure/Cobas TaqMan), G10–15 IU/mL (Abbott m2000, dependent on the input
volume), and G20 IU/mL (Roche Cobas AmpliPrep/Cobas TaqMan) [24–26]
(Table 2). However, we often observe that at the analytical LoD of the Roche
Cobas High Pure/Cobas TaqMan assay, single specimen results may fluctuate
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Table 2. Summary of prognostic and monitoring laboratory tests for directing management of HBV
Testa Detection target Interpretation and comments
Hepatitis B e antigen
(HBeAg)
Soluble protein produced
during acute or chronic
infection
Indicates active viral replication and high
infectivity. Used to assess likelihood of chronic
hepatitis and HBV carriage. HBeAg status




Antibody produced in response







HBV protein produced during
infection; either virion-associated,
subviral, or via integrated viral
DNA in the host genome.
qHBsAg varies with HBV genotype and infection
phase and should be used together with HBV
DNA levels for interpretation of results.
Absolute qHBsAg values (IU/mL) and rate of




Antibody produced in response
to the hepatitis B core
antigen (HBcAg)
Indicator of past, resolved, or persistent HBV
infection. Baseline anti-HBc levels may
indicate the magnitude of host immune
response against HBV, predicting response to
therapy. qAnti-HBc testing is not routinely





Core antigen associated with
circulating viral particles,
denatured HBeAg and the
p22 core-related protein
qHBcrAg is correlated with HBV DNA in
HBeAg-negative inactive patients and with
cccDNA levels. qHBcrAg is negatively predictive
for PEG-IFN response. Requires standardization
and further study for use as a management tool.
Quantitative hepatitis B
viral DNA
Hepatitis B viral genetic material HBV viral load, ALT, and HBeAg status together
with fibrosis state establish treatment
initiation and procedures. qHBV DNA is used to
monitor and manage therapy and post-therapy





Mutations in the HBV polymerase
associated with resistance to: LAM
(L80V/I, V173L, L180M, A181T/V,
M204V/I); ADV (A181T/V, N236T); ETVb
(T184S/A/I/L/G/C/M, S202C/G/I,
M250I/V); and TDFc (A181T/V, N236T)
Select/modify appropriate treatment in patients
who have been treated previously or in those





The most common basal core promoter
mutation, A1762T/G1764A, and the
precore stop codon mutation, G1896A
These mutations may influence immune response
and disease outcome. G1896A and
A1762T/G1764A abolish and reduce expression
of HBeAg, respectively. Both mutations are
associated with different HBV genotypes, and
A1762T/G1764A is significantly associated
with an increased HCC risk.
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between Btarget not detected^ (TND) and BG6.0 IU/mL^ upon duplicate testing
(data not published). The cost of these assays is substantial, and as a result,
samples are rarely duplicate tested; therefore, quantification results close to the
LoD should be interpreted with caution. Despite an observed high correlation
between Roche and Abbott HBV DNA quantification assays, discrepancies have
been described in patients undergoing antiviral therapy, such that 25/134
(18.7 %) NA-treated patients had no detectable HBV DNA by the Roche assay
but were persistently positive with the Abbott test [27, 28]. These differences
may be indirectly associated with the effect of long-term NA therapy and
selective pressures upon the viral genome [29]. We have also observed discrep-
ancies in the HBV DNA level, especially in samples having G6.0 IU/mL as
detected by the Roche Cobas High Pure/Cobas TaqMan assay, and were able
to link these differences directly to nucleotide variation within the region of the
reverse primer used in the quantification assay (data not published) [30].
Management guidelines do specify that Bassays of lower sensitivity are not
recommended^ for monitoring during therapy; however, it is unknown wheth-
er use of Bmore^ sensitive HBV DNA assays would be clinically relevant. A
correlation between the level of HBV DNA at the time of treatment cessation,
based on the limit of detection of the assay used in the study, and the risk for
relapse has not been fully investigated. However, it is clear that relapse rates
remain highly variable after controlling for differing definitions of virological
relapse and viral load LoDs defining undetectable DNA [31]. For example,
studies by Chi et al. and Seto et al., investigating HBeAg-negative patients
discontinuing NA therapy, used G200 and G20 IU/mL, respectively, as the
definition of undetectable DNA. Chi et al. observed 54 % of patients to relapse
after 1 year, while Seto et al. observed 91.4 % of patients to relapse within
48 weeks [32••, 33]. The variation observed in these and numerous other
studies, all of which followed suggested management guideline endpoints,
illustrates the lack of association between an undetectable HBV DNA IU/mL
value and risk of relapse. However, differences in study design and population,
duration of therapy or consolidation, and different endpoint definitions likely
contribute to the variability observed [31].
Table 2. (Continued)
Testa Detection target Interpretation and comments
HBV genotyping Complete HBV genome or the HBsAg
coding region
Identify HBV genotype (A–H) for epidemiologic
and prognostic purposes. Certain HBV
genotypes have been shown to respond better
to PEG-IFN therapy or to be associated with
more severe disease outcomes.
aAll tests use plasma or serum
bResistance to ETV occurs in the presence of L180 and M204 mutations together with a combination of the listed mutations
cMutations may result in reduced susceptibility. Clinical resistance to TDF has not been reproducibly demonstrated
Laboratory Tests used in Monitoring Hepatitis B Response Osiowy et al. 181
Role of residual HBV DNA at treatment cessation
Despite this lack of association, the clinical relevance of minimal residual viremia
at the time of treatment cessation and during off-treatment follow-up is still a
question of interest. Few studies have looked at viral rebound after NA treatment
achievedHBVDNA inhibition below the PCR LoD, defined as TNDor G10 IU/mL
by the most sensitive assays. Undetectable HBV DNA in Chinese NA-treated
patientswas investigated in a retrospective study, which re-analyzed samples using
a highly sensitive PCR assay and reported residual HBV viremia in 41.7 % with a
significantly higher detectable rate and mean level of HBV DNA in the relapse
group compared to the non-relapse group [34]. Another study involving 120
Chinese patients receiving ETV treatment reported a similar rate of residual HBV
viremia—34.2% [35]. Contrary to these studies, residualHBV viremiawas present
in 94% of German patients who were previously presumed to have undetectable
HBV DNA (LoD 60–80 IU/mL) after NA treatment. Upon re-testing the samples
with a sensitive real-time PCR (LoD G10 IU/mL; Abbott), continuously detectable
residual HBV DNA was demonstrated in one third of the patients in all samples
throughout the treatment (11–111 months), while the rest had complete sup-
pression of the viral replication in at least one of several consecutive samples [36].
It should be noted that while themajority of the sampleswere positivewith values
lower than the LoD of the previous PCR assay, some had values well above that
LoD. The median residual viremia levels among HBeAg-positive and HBeAg-
negative patients were 16 (1–197) and 9 (1–549) IU/mL, respectively. Although
such discrepancies are not unusual considering the expected higher variation with
minimal residual viremia, this makes it more difficult to determine which mar-
ginal level of virus replication may be associated with viral rebound or sustained
response. Considering the lack of association with HBV DNA levels
(G200 IU/mL) and relapse as described earlier, further residual DNA
studies with larger patient populations will be needed to confirm this
finding or determine what role trace HBV DNA has in virological
relapse.
Quantitative HBsAg monitoring of treatment response to Peg-IFN
Standardized qHBsAg assays have only recently become commercially available
(Table 2), and they cannot distinguish between the different forms of HBsAg
produced either virion associated, subviral forms or produced from integrated
sequences [37, 38]. Serum qHBsAg appears to be more strongly correlated with
intrahepatic HBV covalently closed circular DNA (cccDNA) levels in HBeAg-
positive patients compared to HBeAg-negative patients. This is possibly due to
more viral integration events as well as the presence of more virus-associated
HBsAg in highly viremic HBeAg-positive patients. Our studies and others have
shown that the qHBsAg varies with HBV genotype and with CHB disease phase
[39–41]. The levels are highest in the immune tolerance phase, with a decline
during the immune clearance phase and a slowprogressive decrease after HBeAg
seroconversion [42, 43••]. Recent studies suggest that a single qHBsAgmeasure-
ment (G1000 IU/mL) along with HBV DNA G2000 IU/mL is predictive for
maintenance of inactive carrier status and risk of reactivation (96 % positive
predictive value), reflecting improved host immune control of HBV infection
(Table 3) [44].
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Expert management guidelines for CHB recommend that Peg-IFN be
considered a first option for treatment in selected patients due to the
advantages of a finite duration of therapy and the greater likelihood of
durable HBeAg and HBsAg seroconversions [21, 45]. In HBeAg-positive
patients, a standard duration of a 48-week therapy induces approximate-
ly ≥30 % HBeAg seroconversion, while the same course of therapy is
Table 3. Guidelines for interpretation of quantitative hepatitis B surface antigen testing





(HBV DNA is G2000 IU/mL)




G50–100 IU/mL in Asians)
predicts HBsAg loss at 6 years
Immune-tolerant 4.5–5.0 0.006 (Asian) ∼5 log10 (i.e.,
9100,000 IU/mL) indicates
immune tolerance. Can be
used to differentiate
immune clearance if HBV
DNA is high and ALT is
minimally elevated.
HBeAg-negative/reactivation ∼3.0 – Lower baseline HBsAg predicts






lower risk of relapse
after NA stopped
(Asians)
Decline 90.5 log10 in 2 years
after achieve HBV DNA
suppression assoc. HBsAg
loss (Western European) or
0.166 log10 IU/ mL/year
(Asian)
Rapid decline 91 log10 after
1 year predicts HBsAg loss.
Limited effect on qHBsAg
Peg-IFN HBeAg-positive:
- Week 12 HBsAg 920000
IU/mL (∼4.3 log10) = non-response (Asians)
- Week 12 G300 IU/mL and 24 G1500 IU/mL (3.1 log10)
predicts SVR
- Week 24 non-responder if no HBsAg decline from baseline
and G2 log drop in HBV DNA (genotype D)
HBeAg-negative:
- Week 12 decline 90.5 log10—high response
- Week 12 decline + 2 log drop HBV DNA ∼40 % develop SVR
- G10 IU/mL at week 48 predicted HBsAg loss
HBsAg decline on Rx is
genotype-specific A 9 B, D 9
C, E.
12 week stopping rules
In HBeAg-negative CHB,
qHBsAg may be used to
help predict response.
qHBsAgmay vary in individual patients and require serial monitoring. The qHBsAg should be used together with HBV DNA for interpretation of results.
Published data include studies with genotype A (Africans, North America, European, HIV, IDU); genotypes B, C (Asian); genotype D (Mediterranean
and Eastern Europe); and genotype E (Africans). The published data on immune-active qHBsAg levels are very variable and are not included
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recommended in HBeAg-negative patients having independent predictors
of response, such as younger age and female gender [46, 47]. As Peg-IFN
treatment is also associated with adverse effects, other predictors of
response, such as HBV genotype and pre-treatment HBV DNA and ALT
levels, have been developed to help select those patients best suited for
Peg-IFN treatment [48–50]. Based on this data, a useful Peg-IFN HBV treat-
ment index to predict an SVRhas been developed (www.liver-GI.nl/peg-IFN) [50].
HBV genotype determination is also an important aspect of Peg-IFN treatment
response prediction and all management guidelines recommendHBV genotyping
among patients being considered for IFN therapy, yet many jurisdictions do not
offer this service [7•, 21, 22]. The ten HBV genotypes (A–J) have a distinct
geographic distribution and the natural history of each genotype contributes to
the major transmission mode and associated endemicity often observed in differ-
ent regions of the world [51]. Amap showing the global geographical distribution
of HBV genotypes is shown in Fig. 1. Genotype A was demonstrated to be an
independent risk factor for the progression to chronic infection following trans-
mission and acute infection, possibly due to the increased transmission rate and
persistent viremia that has been described for genotype A [52–54]. Despite
increased chronicity among genotype A-infected individuals, genotype A is asso-
ciated with an increased likelihood of HBsAg seroclearance compared to other
genotypes, particularly in patients treated with Peg-IFN [50]. Similarly, genotype
B-infected individuals have demonstrated a higher likelihood of stable HBsAg
seroclearance compared to genotype C-infected patients [55].
Fig. 1. Global geographical distribution of HBV genotypes. The map of genotype distribution and prevalence was determined
through literature review and published in a previous study of acute hepatitis B infection in British Columbia, Canada [99]. The
figure is reproduced with permission from John Wiley and Sons.
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Quantitative HBsAg levels have recently been shown to provide an accurate
prediction of response to Peg-IFN. Baseline qHBsAg levels G20,000 IU/mL have
been correlated with achievement of SVR at 6 months post-treatment [56]. The
decline in qHBsAg is particularly useful as an on-treatment biomarker and nega-
tive predictive stopping rule [57]. Thus, a lack of qHBsAg decline byweek 12 and a
G2-log10 decline in HBV DNA indicates subsequent non-response (95–100 %
negative predictive value) in both HBeAg-positive and HBeAg-negative patients
(Table 3) [58–60]. A proposed algorithm for using qHBsAg to guide response to
Peg-IFN treatment is provided (Fig. 2a).
Fig. 2. a Proposed clinical algorithm for qHBsAg monitoring during Peg-IFN therapy and early stopping rule at 12 weeks for
prediction of a sustained virologic response (q quantify). b Proposed clinical algorithm for cessation of long-term NA therapy based
on qHBsAg monitoring and HBV DNA testing according to a sensitive clinical PCR assay (q quantify).
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Quantitative HBsAg monitoring of treatment response to NAs
Oral NAs directly inhibit HBV reverse transcriptase activity during infection and
so have the advantage of rapidly reducing HBV replication resulting in reduced
HBV DNA levels and normalization of serum ALT. Current management guide-
lines recommend either ETV or TDF as an initial therapy for the treatment of
naïve patients due to their potency and high genetic barrier to resistance [21, 22,
61]. NA treatments are not considered to readily Bcure^ or eradicate HBV
infection, due to the persistence of the HBV replication cycle intermediate,
cccDNA, which is not targeted by NAs [62]. Long-term or indefinite treatment
is recommended in order to reach secondary endpoints, such as HBeAg sero-
conversion and undetectable HBVDNA, at which time treatment cessationmay
be considered (Table 1).
A more rapid HBsAg decline in the first year after starting NA or a reduction
rate of 90.166 log10IU/mL/year may predict subsequent HBsAg loss [63]. In
studies involving Asian patients, a qHBsAg level G2 log10IU/mL predicted lower
risk of increased virological and biochemical responses after stopping NA
therapy with 93 % probability of achieving an off-treatment SVR [38, 64–66].
In European patients, with HBV genotype D infection, qHBsAg titres G1000 IU/
mL could predict remission and a subsequent HBsAg loss [67]. Although
differences in inclusion criteria limited comparison across studies, NA-treated
HBeAg-positive patients show greater qHBsAg decline compared to HBeAg-
negative patients, especially with higher baseline ALT levels [68]. As noted in
our studies and others, there are genotype-specific differences in HBsAg kinetics
in response to NA therapy; thus, more studies in regions with a multiethnic
genotype distribution, such as Canada, are needed to confirm the results of
Asian studies [39, 41, 69]. Further long-term prospective evaluation is also
needed regarding the impact of baseline HBsAg levels and the kinetics of
qHBsAg decline in identifying patients who will have a durable off-treatment
NA response. A proposed algorithm for using qHBsAg to guide response to NAs
is provided (Fig. 2b).
Discontinuation of NA therapy: rules
Understanding the factors necessary for an enduring clinical response to
allow the discontinuation of NA treatment is critical, as lifelong therapy
has potential drawbacks, such as maintaining compliance and ongoing
financial costs [65, 70]. In order for treatment cessation to be consid-
ered, defined stopping rules have been suggested based on clinical
studies over the past several years. It is agreed that patients having
decompensated cirrhosis, regardless of HBeAg status, are excluded from
finite treatment options, due to the risk of liver failure if virological
rebound occurs [7•].
Studies involving ETV and TDF have contributed to current recom-
mendations guiding NA treatment cessation in HBeAg-positive patients.
Treatment discontinuation is suggested for those patients achieving
HBeAg seroconversion together with sustained undetectable HBV DNA,
based on two consecutive measurements at least 6 months apart, and
ALT normalization following at least 1 year but preferably 3 years of
consolidation therapy [71, 72•]. Extended consolidation (93 years) pro-
vided a substantially lower relapse rate compared to G1-year
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consolidation for both HBeAg-positive (25 vs. 54 %; P = 0.063) and
HBeAg-negative patients (24 vs. 57 %; P = 0.036) [32••].
The HBeAg-negative patient population does not have a specific
endpoint for treatment cessation; thus, most management guidelines
recommend lifelong treatment, until sustained HBsAg loss or serocon-
version is achieved [21, 22, 61]. However, the Asian-Pacific Association
for the Study of the Liver (APASL) guidelines have suggested that dis-
continuation of treatment may be considered in HBeAg-negative pa-
tients, following at least 2 years treatment and having documented
undetectable HBV DNA (G12 IU/mL) on 3 separate occasions at least
6 months apart [72•]. Similarly, other associations acknowledge that
undetectable HBV DNA (based on a sensitive PCR assay) and ALT
normalization may be considered practical measures of response in
HBeAg-negative patients [61]. Indeed, undetectable HBV DNA is achiev-
able in a larger percentage of HBeAg-negative patients compared to
HBeAg-positive patients, largely due to their lower baseline DNA levels
[73]. However, studies that followed APASL guidelines for HBeAg-
negative treatment cessation describe high rates (980 %) of virologic
relapse within 48 weeks post-ETV treatment [33, 74]. In such cases, early
virological relapse characterized by low HBV DNA levels (G2000 IU/mL)
in the absence of a marked ALT flare may be an acceptable or even
desirable scenario, allowing for host immune control to suppress viral
replication instead of immediately initiating rescue therapy [75, 76••].
Novel virological/serological tests for monitoring treatment response
Aside fromqHBsAg, there ismuch interest and urgency in findingmore effective
tools to predict treatment response prior to and during treatment, particularly
for NAs. Other non-invasive serological markers, such as HBV core-related
antigen (HBcrAg) and quantitative anti-HBc (qAnti-HBc), have been investigat-
ed for their utility inmonitoring the natural history of infection and response to
treatment (Table 2). Both biomarkers hold promise for predictive therapeutic
management.
A chemiluminescent enzyme immunoassay for quantitative measure-
ment of HBcrAg in serum (Lumipulse G HBcrAg, Fujirebio, Gent, Bel-
gium), which detects core antigen associated with circulating viral parti-
cles, as well as denatured HBeAg and the p22 core-related protein,
following detergent pre-treatment, provides a surrogate measure of the
level of transcription and translation of the precore/core coding region
within hepatocytes [77, 78]. This is reflected in the positive correlation
between HBcrAg and HBV DNA levels in HBeAg-negative inactive pa-
tients and with cccDNA levels [79–81]. In this regard, increasing HBcrAg
levels over time have been shown to be an independent risk factor for
developing HCC [82]. Several studies have demonstrated a risk of re-
lapse following NA treatment withdrawal with HBcrAg levels 93.4–3.7
log10U/mL, such that lower HBcrAg levels either before treatment initi-
ation or at the end of treatment correlated with therapeutic response
[83–86, 87•]. As absolute HBcrAg levels are reduced in the presence of
precore or basal core promoter mutants due to eradication of HBeAg
expression, supplementary mutation testing of patients may be required
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to fully understand individual patient results and ultimately for HBcrAg
to be used as a management tool [81, 86]. Although several studies have
shown a moderate correlation between HBcrAg and qHBsAg levels, one
study has shown a greater negative predictive likelihood with week 12
HBcrAg values (98.0 log10U/mL) as compared to week 12 qHBsAg levels
(94.3 log10U/mL) at 94.4 and 80.0 %, respectively, for predicting re-
sponse to Peg-IFN treatment [79–81]. Thus, monitoring of HBcrAg levels
may offer a more robust predictor of virological response during therapy
and potential development of HCC.
Quantitative anti-HBc levels can be measured using a commercially
available immunoassay (Wantai, Beijing, China) and have been found to
be a sensitive and specific indicator of the host immune response. Anti-
HBc production is significantly higher during the immune clearance
phase and during HBeAg-negative active infection, as compared to the
immune tolerant or low replicative phases of infection. Similarly, qAnti-
HBc levels are significantly associated with liver enzyme levels during
the immune clearance phase [88–90]. Several studies have investigated
the utility of baseline qAnti-HBc to predict response to treatment. In
studies of patients treated with Peg-IFN, patients who seroconverted
from HBeAg positivity to anti-HBe positivity, following end of treatment
or follow-up, had significantly higher levels of qAnti-HBc at baseline.
Furthermore, qAnti-HBc levels at baseline were considered to be the best
independent predictor of HBeAg seroconversion following either Peg-IFN
or telbivudine/ADV treatments compared to the baseline predictive value
of ALT or HBV DNA levels, with a predictive threshold value of qAnti-
HBc at baseline proposed (≥4.4–4.5 log10IU/mL) [91, 92]. Using qAnti-
HBc as a surrogate marker of the overall immune response may allow
for more effective prediction of achieving response to therapy and has
been shown to be independent of HBV genotype, unlike qHBsAg, and to
have a longer half-life in serum, as compared to ALT [90, 93].
Conclusions
Over the past decade, clinical studies and research investigations have
provided an improved understanding of how best to use current antiviral
therapies for HBV. However, until new treatments are developed for novel
targets associated with HBV infection, such as cccDNA, host immune
effectors, modified direct-acting antivirals, or viral entry, assembly or secre-
tion inhibitors, management of patients on current antiviral therapies will
continue to require careful monitoring and laboratory testing [94–98]. The
virological monitoring tests, including HBV serological markers, quantitative
HBV DNA, and qHBsAg, continue to improve in terms of sensitivity and
linear range. Highly sensitive HBV DNA assays should be used to deter-
mine the association and level of residual viremia with relapse, and wheth-
er a TND quantification result is essential for complete suppression of viral
replication and SVR. Increasing data from clinical studies indicate that both
HBV genotyping and qHBsAg monitoring may not be available in most
clinical diagnostic labs yet may be useful for predicting CHB natural history
and monitoring on-treatment response, and hence, should be available to
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expert providers. Potential serological markers under development offer the
prospect of increased predictive value for treatment response and will
complement present monitoring methods.
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